Managing Allergic Rhinoconjunctivitis with Accelerated Subcutaneous Immunotherapy

Abstract

Subcutaneous immunotherapy (SCIT) is a powerful treatmentoption for people with refractive allergic rhinoconjunctivitis.Immunotherapy is the only therapy that can modulate theimmune response and develop immune tolerance to commonaeroallergens such as pollen, dander, and dust mites for longerlasting results. Although the minimum treatment period forSCIT has been identified to be 3 years, there are still questionsregarding how long the beneficial effects of SCIT lasts afterdiscontinuation of therapy. There are also risks and benefits tovarious accelerated SCIT dosing schedules, including cluster and rushdosing. My presentation aims to be a comprehensive resource forproviders that need a better alternative to pharmacotherapy forrefractive allergic rhinitis and/or conjunctivitis